Ilant Health, a New York-based value-based obesity treatment company, has raised $15 million in Series A funding to accelerate the expansion of its AI-supported precision care platform for employers and health plans. The financing brings the company’s total funding to more than $22 million and will support continued growth as demand increases for comprehensive obesity and cardiometabolic care that delivers measurable clinical outcomes while reducing healthcare costs.

The Series A round was led by Cornucopian Capital, with participation from naturalX Health Ventures, PeakBridge, SEMCAP AI, Evidenced, Operator Partners, as well as existing investors Celtic House Venture Partners, LifeX Ventures, and AlphaLab. The investment reflects growing confidence in Ilant Health’s approach to addressing obesity through integrated, personalized care that combines technology with multidisciplinary clinical support.

Founded in 2022, Ilant Health was established to transform obesity care from a series of disconnected interventions into a continuous, coordinated model focused on long-term outcomes. The company works with employers and health plans to identify members who would benefit from obesity treatment and guide them toward individualized care pathways that address medical, behavioral, and lifestyle needs. Rather than centering treatment on a single intervention, Ilant offers access to obesity medicine physicians, behavioral health specialists, registered dietitians, peer navigators, pharmacotherapy, intensive behavioral therapy, and bariatric surgery when clinically appropriate.

The company’s platform leverages artificial intelligence to support precision medicine by continuously adapting treatment recommendations based on each individual’s health profile, preferences, and progress. By integrating clinical data with ongoing monitoring and care coordination, Ilant aims to improve patient outcomes while helping employers and insurers manage one of the largest drivers of healthcare spending. Obesity is associated with numerous chronic conditions, including type 2 diabetes, cardiovascular disease, sleep apnea, and musculoskeletal disorders, making effective long-term management increasingly important for healthcare systems.

The newly secured capital will be used to expand Ilant Health’s technology platform, enhance its AI capabilities, grow its multidisciplinary care team, and accelerate commercial expansion across employer and payer markets. The company also plans to invest in additional product development and operational capabilities that support more personalized care delivery and scalable implementation for health plans and self-insured employers nationwide.

Ilant positions itself as a value-based healthcare company that aligns clinical outcomes with financial performance. Instead of emphasizing medication utilization alone, the company combines evidence-based treatment options with personalized care plans designed to improve long-term health while reducing unnecessary healthcare expenditures. Its technology platform supports clinicians by helping identify the most appropriate interventions for each patient and adapting those recommendations as health conditions evolve over time.

The company serves employers and health plans across the United States, helping organizations manage rising costs associated with obesity and cardiometabolic disease. By providing a single point of access to comprehensive obesity care, Ilant seeks to simplify what has traditionally been a fragmented patient experience while improving engagement, adherence, and measurable health outcomes.

The rapid adoption of GLP-1 medications has increased demand for comprehensive obesity management programs capable of integrating pharmacotherapy with behavioral support, nutrition counseling, and long-term monitoring. Ilant believes that sustainable outcomes require more than medication alone and has built its care model around coordinated, multidisciplinary treatment pathways tailored to individual patient needs.

Investor support reflects increasing interest in healthcare companies applying artificial intelligence to improve care delivery while addressing major cost drivers across the healthcare system. The combination of new investors and continued participation from existing backers demonstrates confidence in Ilant’s technology-enabled approach and its potential to improve obesity treatment through precision medicine and value-based care.

With fresh Series A financing, Ilant Health plans to continue expanding its reach, strengthen its AI-powered platform, and deepen partnerships with employers and health plans. As obesity and related cardiometabolic conditions continue to affect millions of people across the United States, the company aims to provide a scalable model that improves access to personalized treatment, delivers better clinical outcomes, and helps reduce the long-term economic burden associated with chronic disease.

Related Articles